Zoetis Inc. · NYSE:ZTS
Zoetis — Merger or Acquisition (May 2018)
11 slides from Zoetis's merger presentation, May 16, 2018
Slide 1: Zoetis to Acquire Abaxis
ZOETIS TO ACQUIRE ABAXIS May 16, 2018 1 1
Slide 2: Accelerating Growth Together
ACCELERATING GROWTH TOGETHER 2 2
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements included in this communication which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933
Slide 4: Non-GAAP Financial Information
NON-GAAP FINANCIAL INFORMATION We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, adjusted operating expenses, adjusted gross margin, and operational results (which excludes the impact of foreign exchange) to assess and analyze our results and trend
Slide 5: Participants in the Solicitation
PARTICIPANTS IN THE SOLICITATION Abaxis, Zoetis and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Abaxis’ directors and executive officers is availa
Slide 6: Key Transaction Themes
KEY TRANSACTION THEMES The second largest global provider of Veterinary Point-of-Care Diagnostic Instruments Purchase price of $83 per share, or approximately $2.0 billion of Equity Value and $1.8 billion of Enterprise Value, subject to the terms and conditions of the merger agreement Brings t
Slide 7: Review of the Global Companion Animal Diagnostics Opportunity
REVIEW OF THE GLOBAL COMPANION ANIMAL DIAGNOSTICS OPPORTUNITY THE INTERNATIONAL MARKET REMAINS UNDERSERVED WITH MEDICALIZATION RATES BELOW THE US… COMPANION ANIMAL POPULATION MEDICALIZED1 Key Takeaways 40% Medicalization 4x ~$3bn+ Global Market2 Larger 71% Medicalization ~10% Historical Growth2
Slide 8: Zoetis Continues to Address Customer Needs with Integrated Innovations
ZOETIS CONTINUES TO ADDRESS CUSTOMER NEEDS WITH INTEGRATED INNOVATIONS COMPREHENSIVE PORTFOLIO AND APPROACH TO CONTINUUM OF CARE PREDICT PREVENT DETECT TREAT GENETICS VACCINES, DATA DIAGNOSTICS MEDICINES ROBOTICS & ANALYTICS AUTOMATION & SENSORS INTERNAL8 CAPABILITIES COMPLEMENTED WITH EXTERNAL PART
Slide 9: Transaction Summary
TRANSACTION SUMMARY TRANSACTION • Purchase Price of $83.00 per share TERMS • Expected closing by the end of 2018 (subject to customary closing conditions) FINANCING • Intend to fund the purchase through a combination of existing cash and new debt OVERVIEW • Expect to end the year within our steady-s
Slide 10: Q&A
Q&A 10 10
Slide 11: Zoetis
zoetis